Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 29;31(10):602.
doi: 10.1007/s00520-023-08068-9.

Use of patient-reported outcome measures for oncology drugs receiving accelerated approval

Donald C Moore  1 , Joseph B Elmes  2 , Scott A Strassels  3 , Jai N Patel  4
Affiliations

Use of patient-reported outcome measures for oncology drugs receiving accelerated approval

Donald C Moore et al. Support Care Cancer. .

Abstract

Patient-reported outcomes (PROs) represent an important evaluation of health-related quality of life that has become more commonly incorporated into oncology drug clinical trials. The frequency of PRO inclusion as an endpoint in oncology drug clinical trials leading to the initial accelerated approval of a new therapy is not yet known. We conducted a cross-sectional study evaluating all new drug applications submitted to the FDA over the past 10 years (2013-2022) that led to the initial approval of an oncology drug through the accelerated approval process. The objective was to assess whether the trials leading to such an approval included PROs. Between 2013 and 2022, the FDA approved 59 unique drugs for an oncology indication via the accelerated approval pathway, and 35 (59%) included a PRO assessment in the clinical trial. A median of 1 PRO measurement was used in each trial, with 23 different types of PRO assessment tools were used across the 59 new drug applications. In summary, we found that PRO measurements are inconsistently utilized in trials leading to initial accelerated approval of oncology drugs, and there seems to be a lack of harmonization of different PRO measurement tools used across trials.

Keywords: Health-related quality of life; Oncology-related drugs; Patient-reported outcomes.

PubMed Disclaimer

References

    1. Beaver JA, Howie LJ, Pelosof L et al (2018) A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol 4(6):849–856 - DOI - PubMed
    1. Basch E (2018) Patient-reported outcomes: an essential component of oncology drug development and regulatory review. Lancet Oncol 19(5):595–597 - DOI - PubMed
    1. U.S. Department of Health and Human Services Food and Drug Administration. Core patient-reported outcomes in cancer clinical trials: guidance for industry, draft guidance. June 2021. Available at: www.fda.gov/media/149994/download . Accessed 24 Aug 2023
    1. EQUATOR Network. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
    1. Food and Drug Administration. Drugs@FA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/ . Accessed 15 Apr 2023

LinkOut - more resources